Form 4: TriSalus Director Stansky Boosts Stake

TriSalus Life Sciences Director Michael P. Stansky acquired additional common stock directly and indirectly through an LLC on February 23, 2026, increasing his beneficial ownership to 986,830 shares.

Summary

• Michael P. Stansky, a Director and 10% Owner of TriSalus Life Sciences, Inc. (TLSI), reported transactions on February 23, 2026.
• Stansky directly acquired 243,900 shares of Common Stock at a price of $4.1 per share.
• An additional 117,198 shares of Common Stock were acquired indirectly by Skyview Investments LLC, where Mr. Stansky serves as managing member, also at $4.1 per share.
• Following these transactions, Mr. Stansky's direct beneficial ownership stands at 787,132 shares.
• His indirect beneficial ownership through Skyview Investments LLC is 199,698 shares, bringing his total beneficial ownership to 986,830 shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Significant insider buying by a Director and 10% Owner indicates high confidence in the company's valuation and future performance.

Positives

• A Director and 10% Owner, Michael P. Stansky, significantly increased his stake in TriSalus Life Sciences, Inc. through direct and indirect purchases.
• The acquisition of 361,098 shares (243,900 direct + 117,198 indirect) at $4.1 per share demonstrates strong insider confidence in the company's future prospects.
• The total beneficial ownership of 986,830 shares by a key insider reinforces alignment of management interests with shareholder value.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or operations.

Industry Context

StockSavvy.ai notes that significant insider buying, especially from a Director and 10% Owner, is generally viewed positively by the market. It often signals that those with intimate knowledge of the company believe the stock is undervalued or that positive developments are on the horizon, contrasting with broader market trends where insider selling might indicate concerns.

Comparison to Industry Standards

• Insider buying activity, particularly by a director with a substantial stake, is a common indicator of management's confidence in their company's prospects, aligning with similar signals observed across various industries.
• While specific comparable companies or projects are not detailed in this filing, a purchase of over $1.4 million in stock by an insider is a notable transaction size, often exceeding typical open-market purchases by individual executives in companies of similar market capitalization.

Related Party Transactions

• The indirect acquisition of 117,198 shares by Skyview Investments LLC is a related party transaction, as Michael P. Stansky serves as the managing member of the LLC and is deemed to beneficially own these securities.

Stakeholder Impact

• Shareholders may view this as a positive sign of management confidence, potentially leading to increased investor interest and a more stable share price.
• The increased alignment of a key director's financial interests with the company's performance could benefit all stakeholders by encouraging decisions focused on long-term value creation.

Key Dates

Recommendation

The substantial insider buying by a Director and 10% Owner, Michael P. Stansky, signals strong confidence in TriSalus Life Sciences' future. Such a significant investment by someone with deep knowledge of the company's operations and prospects suggests the stock may be undervalued or poised for positive developments, making it an attractive 'buy' for seasoned investors.

Keywords

TriSalus Life Sciences, TLSI, Insider Buying, Form 4, Beneficial Ownership, Director Stock Purchase, Equity Acquisition, Michael P. Stansky, Skyview Investments LLC